The pharmaceutical intermediate market was valued at US$ 27,356.70 million in 2020 and is projected to reach US$ 37,290.33 million by 2028; it is expected to grow at a CAGR of 4.2% from 2021 to 2028.
The rising prevalence of chronic diseases and infectious diseases, and escalating investment by pharmaceutical companies in R&D activities drive the growth of the pharmaceutical intermediate market. However, the high cost of drug manufacturing hinders the market growth.
Pharmaceutical intermediates are the building blocks of active pharmaceutical ingredients (APIs).These are raw materials that undergo molecular change or processing during bulk drug production.
Thus, the requirement of pharmaceutical intermediates increases with the rise in demand for drugs to treat chronic diseases.As per the Centers for Disease Control and Prevention (CDC), 6 in 10 adults in the US suffer from at least one chronic disease such as cancer, heart disease, lung disease, stroke, neurological disease, diabetes, and kidney diseases.
Moreover, 4 in 10 adults in the country have two or more chronic diseases.Additionally, according to the press release by the European Chronic Disease Alliance (ECDA), in 2014, 9 out of 10 people in Europe die due to chronic diseases.
Thus, 70–80% of the total healthcare costs are spent on the management of chronic diseases. The surging prevalence of infectious diseases, especially in Southeast Asia, is also likely to propel the demand for APIs in the coming years, eventually driving the growth of the pharmaceutical intermediate market. For instance, as per the Revised National Tuberculosis Control Programme Report, around 4.4 lakh patients died due to tuberculosis in India in 2018, that is 29% of the total 1.5 million deaths caused by the disease across the world. Thus, such high prevalence of chronic diseases and infectious diseases is bolstering the demand for drugs, eventually highlighting the need of pharmaceutical intermediates. Based on type, the pharmaceutical intermediate market is bifurcated into GMP and non GMP counters.In 2020, GMP accounted for a larger share in the market owing to increase in the adoption of good manufacturing practices (GMP) by pharmaceutical companies.
These regulations are designed to reduce the risks involved in the production of pharmaceuticals that cannot be eliminated through testing the finished product. In terms of application, the pharmaceutical intermediate market is segmented into antibiotics, antipyretic analgesics, vitamins, and others. The antibiotics segment held the largest share of the market in 2020, whereas the vitamins segment is estimated to register the highest CAGR in the market during the forecast period. World Health Organization (WHO), European Chronic Disease Alliance (ECDA), US Food and Drug Administration (FDA), Pharmaceutical Research and Manufacturers Association (PhRMA), US Census Bureau, the Germany Trade & Invest (GTAI), European Medicine Agency (EMA), and Institute for Integrated Economic Research Australia are among the major secondary sources referred to while preparing the report on the pharmaceutical intermediate market.
Our reports have been used by over 10K customers, including:
The implementation of track and trace solutions and technologies is an important strategy adopted by many manufacturing companies and regulatory bodies in recent years. The global track and trace solutions market is projected to reach USD 7.3 billion by 2026 from USD 4.1 billion in 2021, at a CAGR of 12.1% during the forecast period. Growth...
The global single-use assemblies market is projected to reach USD 6.3 billion by 2026 from USD 2.2 billion in 2021, at a CAGR of 23.3% during the forecast period. The growth of the single-use assemblies market can primarily be attributed to the major advantages of single-use technologies as compared to traditional stainless-steel assemblies,...
The global pharmaceutical intermediates market is expected to reach US$ 37,290.33 million in 2028 from US$ 27,356.70 million in 2020. The market is estimated to grow with a CAGR of 3.95% during 2020-2028. Countries in Asia Pacific are emerging as attractive outsourcing locations for pharmaceuticals and biopharmaceuticals industries. Low manufacturing...
The global polymeric adsorbents market size is projected to grow from USD 120 million in 2021 to USD 162 million by 2026, at a Compound Annual Growth Rate (CAGR) of 6.18%. The global polymeric adsorbents industry has witnessed high growth primarily because of the booming industrial sector, rise in the demand for wastewater treatment, and rapid...
The Global Pharmaceutical CDMO Market was valued USD 160.12 billion in 2020, and it is expected to reach USD 236.61 billion by 2026, registering a CAGR of 6.5%, during the period of forecast period (2021-2026). The CMO/CDMO service sector is uniquely positioned to address some of the challenges that drug developers are facing amid the COVID-19...
238 pages •
By Asia Market Information & Development Company
• Jun 2021
China’s demand for Emerging Pharmaceuticals has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer...
Japan - Healthcare, Regulatory and Reimbursement Landscape
The analyst has released its latest report, "Japan - Healthcare, Regulatory and Reimbursement Landscape".The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in...
The Formulation Development Outsourcing market was valued at approximately USD 8,055 million in 2020 and is expected to witness a revenue of USD 12,650 million in 2026, with a CAGR of 7.2% over the forecast period. The rapidly evolving threat of COVID-19 is impacting lives, communities, businesses, and industries around the world. The...
The Pharmaceutical Glass Vials and Ampoules Market was valued at USD 10.8 billion in 2020 and expected to reach USD 15.96 billion by 2026 and grow at a CAGR of 6.8% over the forecast period (2021 - 2026). The introduction of stringent laws to enhance the quality and integrity of domestically manufactured drugs is primarily leading to an increase...
249 pages •
By Asia Market Information & Development Company
• May 2021
China’s demand for Therapy has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption and...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.